The clinical spectrum and natural history of early-onset diseases due to DNA polymerase gamma mutations

• Published in: Genetics in medicine Vol. 19; no. 11; pp. 1217 - 1225
• Main Authors: Hikmat, Omar, Tzoulis, Charalampos, Chong, Wui K, Chentouf, Latifa, Klingenberg, Claus, Fratter, Carl, Carr, Lucinda J, Prabhakar, Prab, Kumaraguru, Nandhini, Gissen, Paul, Cross, J Helen, Jacques, Thomas S, Taanman, Jan-Willem, Bindoff, Laurence A, Rahman, Shamima
• Format: Journal Article
• Language: English
• Published: New York Nature Publishing Group US 01.11.2017; Elsevier Limited
• Subjects: 631/208/2489/144; 631/208/737; 692/1807/1693; 692/700/1720; Biomedicine; Child; Child, Preschool; Developmental Disabilities - genetics; Developmental Disabilities - physiopathology; Disease; DNA Polymerase gamma - genetics; Female; Genotype; Human Genetics; Humans; Infant; Laboratory Medicine; Magnetic Resonance Imaging; Male; Mitochondrial Diseases - enzymology; Mitochondrial Diseases - genetics; Mitochondrial Diseases - pathology; Mitochondrial Diseases - physiopathology; Muscle, Skeletal - pathology; Mutation; original-research-article; Phenotype; Retrospective Studies; Alpers; myocerebrohepatopathy syndrome; mtDNA depletion; infantile hepatocerebral syndromes; mitochondrial disease
• ISSN: 1098-3600; 1530-0366; 1530-0366
• DOI: 10.1038/gim.2017.35

Purpose Mutations in POLG, the most common single-gene cause of inherited mitochondrial disease, are diagnostically challenging owing to clinical heterogeneity and overlap between syndromes. We aimed to improve the clinical recognition of POLG -related disorders in the pediatric population. Methods We performed a multinational, phenotype: genotype study using patients from three centers, two Norwegian and one from the United Kingdom. Patients with age at onset <12 years and confirmed pathogenic biallelic POLG mutations were considered eligible. Results A total of 27 patients were identified with a median age at onset of 11 months (range 0.6–80.4). The majority presented with global developmental delay ( n =24/24, 100%), hypotonia ( n =22/23, 96%) and faltering growth ( n =24/27, 89%). Epilepsy was common, but notably absent in patients with the myocerebrohepatopathy spectrum phenotype. We identified two novel POLG gene mutations. Conclusion Our data suggest that POLG -related disease should be suspected in any child presenting with diffuse neurological symptoms. Full POLG sequencing is recommended since targeted screening may miss mutations. Finally, we simplify the classification of POLG -related disease in children using epilepsy as the crucial defining element; we show that Alpers and myocerebrohepatopathy spectrum follow different outcomes and that they manifest different degrees of respiratory chain dysfunction.